AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22238574 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 60
Study 20163387 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate treatment
Number of subjects: 601
Study 20163387 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational therapy
Number of subjects: 601
Study 20163387 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsyndromal anxiety (HAM-A 'Anxious Mood' item)
Number of subjects: 601
Study 20163387 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of > or =1 psychiatric antecedent
Number of subjects: 601
Study 20163387 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower pretreatment drinking intensity
Number of subjects: 601
Study 20163387 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline motivation to have abstinence as a goal
Number of subjects: 601
Study 18687249 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillation threshold (DFT) testing during ICD implantation
Number of subjects: 811
Study 18687249 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline DFT testing
Number of subjects: 811
Study 15975299 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganxian recipe (GXR) combined with lamivudine (LVD)
Number of subjects: 120
Study 15975299 — intervention group
Group type: COMPARATOR
Intervention: lamivudine (LVD) alone
Number of subjects: 120
Study 15975299 — intervention group
Group type: COMPARATOR
Intervention: Ganxian recipe (GXR) alone
Number of subjects: 120
Study 12925330 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonparametric function in a semiparametric additive mixed model
Number of subjects: 0
Study 12925330 — intervention group
Group type: COMPARATOR
Intervention: Nonparametric functions in semiparametric additive mixed models for two groups
Number of subjects: 0
Study 11314873 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg citalopram orally 2 hours before ECT
Number of subjects: 10
Study 11314873 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally 2 hours before ECT
Number of subjects: 10
Study 11314873 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg citalopram
Number of subjects: 10
Study 11314873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9006785 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline (500 mg) with standard breakfast
Number of subjects: 12
Study 9006785 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline (500 mg) with cholecystokinin (0.3 micrograms/kg)
Number of subjects: 12
Study 9006785 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release theophylline (500 mg) under fasting conditions
Number of subjects: 12
Study 1428302 — intervention group
Group type: COMPARATOR
Intervention: Isradipine (10 mg single dose)
Number of subjects: 54
Study 1428302 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release nicardipine (40 mg twice daily for six months)
Number of subjects: 54
Study 1428302 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 54
Study 3970345 — intervention group
Group type: COMPARATOR
Intervention: Oxygen and oxygen-enriched air
Number of subjects: 0
Study 3970345 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 0
Study 31206056 — intervention group
Group type: EXPERIMENTAL
Intervention: PSI/reusable (PSR)
Number of subjects: 4
Study 31206056 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use instrumentation (SUI)
Number of subjects: 4
Study 31206056 — intervention group
Group type: COMPARATOR
Intervention: Conventional/reusable instrumentation (CVR)
Number of subjects: 4
Study 29073799 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography decision intervention (personalised risk estimates, varying by amount of information and format)
Number of subjects: 2465
Study 25616935 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of Carbohydrate Quality Index (CQI)
Number of subjects: 6542
Study 25616935 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of Mediterranean diet score
Number of subjects: 6542
Study 25616935 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quintile of Fat Quality Index (FQI)
Number of subjects: 6542
Study 25616935 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CQI or Med-Diet score
Number of subjects: 6542
Study 25616935 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower FQI
Number of subjects: 6542
Study 24929252 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based health management program for 18 months
Number of subjects: 100
Study 24929252 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 100
Study 23272551 — intervention group
Group type: EXPERIMENTAL
Intervention: Gray MTA (ProRoot MTA, Dentsply, Tulsa Dental)
Number of subjects: 28
Study 23272551 — intervention group
Group type: EXPERIMENTAL
Intervention: BioAggregate (Diadent Group International, Vancouver)
Number of subjects: 28
Study 20840207 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 133
Study 20840207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 20840207 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous and point-prevalence abstainers
Number of subjects: 133
Study 20840207 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-abstainers
Number of subjects: 133
Study 17671042 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI1 4G/4G genotype
Number of subjects: 348
Study 17671042 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 348
Study 16128971 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional support from volunteer breastfeeding counselors
Number of subjects: 720
Study 11390120 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerodiol 100 microg/day
Number of subjects: 420
Study 11390120 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerodiol 200-600 microg/day
Number of subjects: 420
Study 11390120 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerodiol 300 microg/day
Number of subjects: 420
Study 11390120 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerodiol 400 microg/day
Number of subjects: 420
Study 11390120 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerodiol 200 microg/day
Number of subjects: 420
Study 11390120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 11390120 — intervention group
Group type: COMPARATOR
Intervention: Oral estradiol 1 mg/day
Number of subjects: 420
Study 11390120 — intervention group
Group type: COMPARATOR
Intervention: Oral estradiol 2 mg/day
Number of subjects: 420
Study 9211475 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Pain Grade questionnaire
Number of subjects: 400
Study 8424908 — intervention group
Group type: EXPERIMENTAL
Intervention: Single agent cisplatinum
Number of subjects: 40
Study 8424908 — intervention group
Group type: COMPARATOR
Intervention: Whole abdomino-pelvic moving strip radiotherapy
Number of subjects: 40
Study 8424908 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 40
Study 3596167 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg) intravenously before tests
Number of subjects: 8
Study 3596167 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg q.i.d., p.o.) for 1 month
Number of subjects: 8
Study 3596167 — intervention group
Group type: COMPARATOR
Intervention: Placebo intravenously before tests
Number of subjects: 8
Study 2724196 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 66
Study 3187 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oxytetracycline a day p.o. for 6 weeks after initial treatment with 1 g oxytetracycline a day p.o. for 1 week
Number of subjects: 50
Study 3187 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 100 mg oxytetracycline and 1.2 g sodiumbituminosulfonates a day p.o. for 6 weeks after initial treatment with 1 g oxytetracycline a day p.o. for 1 week
Number of subjects: 50
Study 3187 — intervention group
Group type: COMPARATOR
Intervention: 100 mg oxytetracycline a day p.o. for 6 weeks after treatment with combination therapy
Number of subjects: 50
Study 30632918 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affect condition
Number of subjects: 44
Study 30632918 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative affect condition
Number of subjects: 44
Study 30632918 — intervention group
Group type: COMPARATOR
Intervention: Neutral affect condition
Number of subjects: 44
Study 29149776 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized 2.5 mg of salbutamol and 2.5 mL of 3% hypertonic saline solution for three consecutive 20-min periods
Number of subjects: 340
Study 29149776 — intervention group
Group type: COMPARATOR
Intervention: Nebulized only salbutamol in the same dose and time as the intervention group
Number of subjects: 340
Study 26068515 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (12 sessions within 48 hours of injury)
Number of subjects: 0
Study 23795663 — intervention group
Group type: EXPERIMENTAL
Intervention: 22G needle
Number of subjects: 135
Study 23795663 — intervention group
Group type: COMPARATOR
Intervention: 25G needle
Number of subjects: 135
Study 21813427 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (up to 4 mg once daily)
Number of subjects: 247
Study 21813427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study 21813427 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 247
Study 19661662 — intervention group
Group type: EXPERIMENTAL
Intervention: External birth defects screening
Number of subjects: 624
Study 19661662 — intervention group
Group type: EXPERIMENTAL
Intervention: External congenital anomalies
Number of subjects: 624
Study 19661662 — intervention group
Group type: EXPERIMENTAL
Intervention: Musculoskeletal abnormalities
Number of subjects: 624
Study 16432350 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass
Number of subjects: 155
Study 16432350 — intervention group
Group type: COMPARATOR
Intervention: Open gastric bypass
Number of subjects: 155
Study 16432350 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 155
Study 15693192 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine extraction and analysis method using high-performance liquid chromatography-electrospray ionization mass spectrometry.
Number of subjects: 0
Study 11378343 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF chemotherapy (cyclophosphamide, methotrexate, and 5-fluorouracil)
Number of subjects: 141
Study 11378343 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF chemotherapy with additional radiotherapy or tamoxifen
Number of subjects: 141
Study 9231451 — intervention group
Group type: EXPERIMENTAL
Intervention: Local alcohol policy interventions
Number of subjects: 0
Study 8492058 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturn-Ring used five times a week over an 8-week exercise program
Number of subjects: 50
Study 8492058 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise alone
Number of subjects: 50
Study 3101849 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplements (200,000 IU orally immediately and again the next day)
Number of subjects: 180
Study 3101849 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment alone (Control)
Number of subjects: 180
Study 3101849 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplements (200,000 IU orally immediately and again the next day) in children aged under 2 years
Number of subjects: 180
Study 3101849 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment alone (Control) in children aged under 2 years
Number of subjects: 180
Study 3101849 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (regardless of allocation) in marasmic children
Number of subjects: 180
Study 29910024 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 577
Study 29910024 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 577
Study 29910024 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 577
Study 27131268 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor plus sitagliptin (GS)
Number of subjects: 174
Study 27131268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 23720411 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose load (75 grams of carbohydrates in 300 mL water)
Number of subjects: 16
Study 23720411 — intervention group
Group type: COMPARATOR
Intervention: Water (300 mL)
Number of subjects: 16
Study 23720411 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose load
Number of subjects: 16
Study 23720411 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 16
Study 23419911 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group performing The11 exercises (2 to 3 sessions per week during one soccer season)
Number of subjects: 479
Study 23419911 — intervention group
Group type: COMPARATOR
Intervention: Control group continuing usual warm-up
Number of subjects: 479
Study 20580111 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT treatment with dose of the day assessment
Number of subjects: 10
Study 18713788 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g/day
Number of subjects: 353
Study 18713788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353
Study 16621327 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of somatostatin to block GH secretion during the first 3 hours of sleep (mainly SWS)
Number of subjects: 0
Study 12691793 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 25‐75 mg/day
Number of subjects: 9
Study 11205648 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (60 mg, 40 mg, and 20 mg in 2-week intervals for 6 weeks)
Number of subjects: 39
Study 11205648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 11205648 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (during steroid treatment)
Number of subjects: 39
Study 11205648 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during steroid treatment)
Number of subjects: 39
Study 9247506 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (target INR 2.0 to 2.5) plus aspirin (150 mg daily)
Number of subjects: 57
Study 9247506 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus aspirin (150 mg daily)
Number of subjects: 57
Study 8233735 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic administration of Curosurf (200 mg/kg body weight)
Number of subjects: 75
Study 8233735 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic administration of Curosurf
Number of subjects: 75
Study 3303425 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (8 mg) administered intramuscularly for 10 days
Number of subjects: 12
Study 3303425 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (40 mg) administered orally for 10 days
Number of subjects: 12
Study 3303425 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections and tablets
Number of subjects: 12
Study 30768224 — intervention group
Group type: EXPERIMENTAL
Intervention: Abicipar 1 mg
Number of subjects: 50
Study 30768224 — intervention group
Group type: EXPERIMENTAL
Intervention: Abicipar 2 mg
Number of subjects: 50
Study 30768224 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab 0.5 mg
Number of subjects: 50
Study 28576627 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 240
Study 28576627 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stent (BES)
Number of subjects: 240
Study 28576627 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS)
Number of subjects: 240
Study 28576627 — intervention group
Group type: COMPARATOR
Intervention: BVS
Number of subjects: 240
Study 28576627 — intervention group
Group type: COMPARATOR
Intervention: EES and BES
Number of subjects: 240
Study 26023904 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 243
Study 26023904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 23980056 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 50
Study 23980056 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 50
Study 22109762 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam orally for 3 months
Number of subjects: 107
Study 22109762 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam plus four intratympanic dexamethasone (ITD) injections
Number of subjects: 107
Study 22109762 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam plus four ITD injections plus four intravenous injections of lipo-prostaglandin E(1)
Number of subjects: 107
Study 19501780 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional water
Number of subjects: 58
Study 16415095 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol succinate 100 mg/day
Number of subjects: 287
Study 16415095 — intervention group
Group type: COMPARATOR
Intervention: No beta-blocker (control)
Number of subjects: 287
Study 12576907 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week multifactorial rehabilitation program
Number of subjects: 60
Study 12576907 — intervention group
Group type: COMPARATOR
Intervention: 10-week multifactorial rehabilitation program
Number of subjects: 60
Study 10856390 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic Thera DR pacemaker
Number of subjects: 16
Study 8799095 — intervention group
Group type: EXPERIMENTAL
Intervention: BOM+
Number of subjects: 0
Study 8799095 — intervention group
Group type: EXPERIMENTAL
Intervention: BOM
Number of subjects: 0
Study 8799095 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 1377245 — intervention group
Group type: EXPERIMENTAL
Intervention: Single preoperative dose of gentamicin and metronidazole
Number of subjects: 103
Study 1377245 — intervention group
Group type: COMPARATOR
Intervention: Three doses of gentamicin and metronidazole
Number of subjects: 103
Study 6462404 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (steroid) administration during and after lumbar discectomy
Number of subjects: 0
Study 6462404 — intervention group
Group type: COMPARATOR
Intervention: No steroid administration (control group)
Number of subjects: 0
Study 31477280 — intervention group
Group type: EXPERIMENTAL
Intervention: 22 unique antibodies (survival-associated antibodies, SAAs) used to stratify patients into low-, medium-, or high-risk survival groups.
Number of subjects: 216
Study 31477280 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic proteomic clusters validated from TCGA data.
Number of subjects: 216
Study 29801482 — intervention group
Group type: EXPERIMENTAL
Intervention: Mwanamphepo (herbal medicine)
Number of subjects: 8219
Study 25777576 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative mid-trimester anomaly (IMTA) chart used during examination
Number of subjects: 25
Study 25777576 — intervention group
Group type: COMPARATOR
Intervention: Standard examination without the IMTA chart
Number of subjects: 25
Study 24249322 — intervention group
Group type: COMPARATOR
Intervention: COPD patients
Number of subjects: 331
Study 24249322 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy subjects
Number of subjects: 331
Study 23145756 — intervention group
Group type: COMPARATOR
Intervention: Standard single bundle ACL reconstruction with hamstring tendon autografts
Number of subjects: 40
Study 23145756 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation technique with hamstring tendon autograft
Number of subjects: 40
Study 20708814 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin administration
Number of subjects: 23
Study 17701421 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle Fuel (MF)
Number of subjects: 9
Study 17701421 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 9
Study 15812753 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular pacing
Number of subjects: 0
Study 15812753 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous biventricular pacing
Number of subjects: 0
Study 15812753 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential biventricular pacing
Number of subjects: 0
Study 15812753 — intervention group
Group type: EXPERIMENTAL
Intervention: CONTAK RENEWAL 2/4/4HE/EASYTRAK 2 system
Number of subjects: 0
Study 11819020 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-stage closed-wedge tibial osteotomy and anterior cruciate ligament reconstruction
Number of subjects: 14
Study 11819020 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibial osteotomy with ligament reconstruction using the Ligament Advanced Reconstruction System
Number of subjects: 14
Study 11819020 — intervention group
Group type: COMPARATOR
Intervention: Tibial osteotomy without ligament reconstruction
Number of subjects: 14
Study 11819020 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibial osteotomy (overall)
Number of subjects: 14
Study 11819020 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-wedge tibial osteotomy
Number of subjects: 14
Study 9861576 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 100 mg/day
Number of subjects: 20
Study 9861576 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 20
Study 9861576 — intervention group
Group type: COMPARATOR
Intervention: Patients with a history of myocardial infarction and/or hypertension
Number of subjects: 20
Study 9088584 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol CR + fluvastatin
Number of subjects: 14
Study 9088584 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol CR + bezafibrate
Number of subjects: 14
Study 9088584 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol + fluvastatin
Number of subjects: 14
Study 9088584 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol + bezafibrate
Number of subjects: 14
Study 9088584 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 2285326 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (interactive instructional activities)
Number of subjects: 0